Evidence map›Paper›PMID 29404777›Full record

ArticlePharmaceutical research2018

Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway.

Mariarosa Anna Beatrice Melone, Clemente Dato, Simona Paladino, Cinzia Coppola, Claudia Trebini, Maria Teresa Giordana, Lorena Perrone

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Thioredoxin-Interacting Protein in Cancer and Diabetes.Antioxidants & redox signaling · 2022
    Review
  16. α-Arrestins and Their Functions: From Yeast to Human Health.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Mariarosa Anna Beatrice MeloneDepartment of Medical, Surgical, Neurological, Metabolic Sciences and Aging, Second Division of Neurology, Center for Rare Neurological e Neuromuscular Diseases and Interuniversity Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, 80100, Naples, Italy.
Clemente DatoDepartment of Medical, Surgical, Neurological, Metabolic Sciences and Aging, Second Division of Neurology, Center for Rare Neurological e Neuromuscular Diseases and Interuniversity Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, 80100, Naples, Italy.
Simona PaladinoDipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80100, Naples, Italy.
Cinzia CoppolaDepartment of Medical, Surgical, Neurological, Metabolic Sciences and Aging, Second Division of Neurology, Center for Rare Neurological e Neuromuscular Diseases and Interuniversity Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, 80100, Naples, Italy.
Claudia TrebiniDepartment of Neuroscience, University Hospital San Giovanni Battista di Torino, 10126, Molinette, Italy.
Maria Teresa GiordanaDepartment of Neuroscience, University Hospital San Giovanni Battista di Torino, 10126, Molinette, Italy.
Lorena PerroneUniversite´Grenoble Alpes, Grenoble, France. perronelorena1@gmail.com.ORCID http://orcid.org/0000-0001-5399-9397
University of Campania "Luigi Vanvitelli" · ITAzienda Ospedaliero Universitaria San Giovanni Battista · ITHeidelberg University · DEUniversity of Naples Federico II · IT

Funding

Marie-Curie International Reintegration grant 224892
6 · The paper itself

Abstract

purposeOxidative stress is a hallmark of Alzheimer's Disease (AD) and promotes tau phosphorylation. Since Thioredoxin Interacting protein (TXNIP), the inhibitor of the anti-oxidant system of Thioredoxin, is up regulated in the hippocampus of AD patients, we investigated whether TXNIP plays a role in promoting tau phosphorylation and whether Verapamil, an inhibitor of TXNIP expression, prevents TXNIP downstream effects.

methodsWe analyzed TXNIP expression and tau phosphorylation in the hippocampus of the 5xFAD mice in the absence and presence of a pharmacological treatment with Verapamil. Using SH-SY5Y cells, we verified the causative role of TXNIP in promoting tau phosphorylation at Ser202/Thr205, by inducing TXNIP silencing.

resultsThe amyloid beta peptide (Aβ

conclusionsOur study unveil a novel pathway involved in AD progression that is inhibited by Verapamil, shedding new light on the understanding of the therapeutic potential of Verapamil in AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsCarrier ProteinsCell Line, TumorDisease Models, AnimalDisease ProgressionHippocampusHumansMAP Kinase Signaling SystemMiceMice, TransgenicMutationOxidative StressPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorAPP protein, humanCarrier ProteinsPeptide FragmentsPresenilin-1PSEN1 protein, humanReactive Oxygen SpeciesSerinetau ProteinsThioredoxinsThreonineTXNIP protein, humanTxnip protein, mouseVerapamilAlzheimer’s diseaseNeuronOxidative stressp38 MAPKTau phosphorylationTXNIPVerapamil

Identifiers

PMID29404777
OpenAlexW2790232798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.